Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2013 Nov 19;81(21 Suppl 1):S41-4. doi: 10.1212/01.wnl.0000435748.79908.c5.

Conclusions and future directions for the REiNS International Collaboration.

Author information

From the Pediatric Oncology Branch (B.C.W., E.D., P.L.W.), National Cancer Institute, Bethesda, MD; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC; and Neurology Department and Cancer Center (S.R.P.). Massachusetts General Hospital, Boston, MA.


The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established with the goal to develop consensus recommendations for the use of endpoints in neurofibromatosis (NF) clinical trials. This supplement includes the first series of REiNS recommendations for the use of patient-reported, functional, and visual outcomes, and for the evaluation of imaging response in NF clinical trials. Recommendations for neurocognitive outcome measures, the use of whole-body MRI in NF, the evaluation of potential biomarkers of disease, and the comprehensive evaluation of functional and patient-reported outcomes in NF are in development. The REiNS recommendations are made based on current knowledge. Experience with the use of the recommended endpoints in clinical trials, development of new tools and technologies, new knowledge of the natural history of NF, and advances in the methods used to analyze endpoints will likely lead to modifications of the currently proposed guidelines, which will be shared with the NF research community through the REiNS Web site Due to the clinical complexity of NF, there is a need to seek expertise from multiple medical disciplines, regulatory agencies, and industry to develop trial endpoints and designs, which will lead to the identification and approval of effective treatments for NF tumor and nontumor manifestations. The REiNS Collaboration welcomes anyone interested in providing his or her expertise toward this effort.

[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center